Technology
Health
Biotechnology

BioXcel Therapeutics

$9.15
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.48 (5.54%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell BTAI and other stocks, options, ETFs, and crypto commission-free!

About BTAI

BioXcel Therapeutics, Inc. Common Stock, also called BioXcel Therapeutics, is a clinical stage biopharmaceutical company focuses on drug development. Read More The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.

Employees
18
Headquarters
New Haven, Connecticut
Founded
2017
Market Cap
143.94M
Price-Earnings Ratio
Dividend Yield
Average Volume
26.63K
High Today
$9.21
Low Today
$8.55
Open Price
$8.74
Volume
8.30K
52 Week High
$12.00
52 Week Low
$2.41

Collections

Technology
Health
Biotechnology
Medical
Therapy
Biopharmaceutical
Cancer Prevention
Pharmaceutical

BTAI News

BenzingaJul 26

BioXcel's CEO On BXCL501: 'This Is A Pretty Unique Drug'

55

BTAI Earnings

-$0.60
-$0.46
-$0.33
-$0.19
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
-$0.60 per share
Actual
-$0.54 per share

More BTAI News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.